Characterization of the humoral immune response to bovine collagen implants

J. P. McCoy, W. J. Schade, R. J. Siegle, T. P. Waldinger, E. E. Vanderveen, Neil Swanson

Research output: Contribution to journalArticle

Abstract

The use of bovine collagen implants (BCIs) for the correction of dermal contour deformities is becoming widespread. A small percentage of patients receiving treatment with BCIs suffer adverse reactions that appear to be of an immune nature. Circulating antibodies to BCIs are found in all patients suffering adverse treatment reactions and in small numbers of normal individuals and BCI-treated patients not suffering adverse reactions. These antibodies are always IgG, although quite often IgA is also present. The anti-BCI antibodies are quite stable, suffering virtually no loss of activity after storage at room temperature for 54 days. Immunoblotting studies indicate that no singular component of the BCI collagen is the prime antigenic component; multiple regions of the collagen molecule are recognized by patients' antibodies.

Original languageEnglish (US)
Pages (from-to)990-994
Number of pages5
JournalArchives of Dermatology
Volume121
Issue number8
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Humoral Immunity
Collagen
Antibodies
Immunoblotting
Immunoglobulin A
Immunoglobulin G
Skin
Temperature
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

McCoy, J. P., Schade, W. J., Siegle, R. J., Waldinger, T. P., Vanderveen, E. E., & Swanson, N. (1985). Characterization of the humoral immune response to bovine collagen implants. Archives of Dermatology, 121(8), 990-994. https://doi.org/10.1001/archderm.121.8.990

Characterization of the humoral immune response to bovine collagen implants. / McCoy, J. P.; Schade, W. J.; Siegle, R. J.; Waldinger, T. P.; Vanderveen, E. E.; Swanson, Neil.

In: Archives of Dermatology, Vol. 121, No. 8, 1985, p. 990-994.

Research output: Contribution to journalArticle

McCoy, JP, Schade, WJ, Siegle, RJ, Waldinger, TP, Vanderveen, EE & Swanson, N 1985, 'Characterization of the humoral immune response to bovine collagen implants', Archives of Dermatology, vol. 121, no. 8, pp. 990-994. https://doi.org/10.1001/archderm.121.8.990
McCoy JP, Schade WJ, Siegle RJ, Waldinger TP, Vanderveen EE, Swanson N. Characterization of the humoral immune response to bovine collagen implants. Archives of Dermatology. 1985;121(8):990-994. https://doi.org/10.1001/archderm.121.8.990
McCoy, J. P. ; Schade, W. J. ; Siegle, R. J. ; Waldinger, T. P. ; Vanderveen, E. E. ; Swanson, Neil. / Characterization of the humoral immune response to bovine collagen implants. In: Archives of Dermatology. 1985 ; Vol. 121, No. 8. pp. 990-994.
@article{bd45cd816b0f4924af0452608764017c,
title = "Characterization of the humoral immune response to bovine collagen implants",
abstract = "The use of bovine collagen implants (BCIs) for the correction of dermal contour deformities is becoming widespread. A small percentage of patients receiving treatment with BCIs suffer adverse reactions that appear to be of an immune nature. Circulating antibodies to BCIs are found in all patients suffering adverse treatment reactions and in small numbers of normal individuals and BCI-treated patients not suffering adverse reactions. These antibodies are always IgG, although quite often IgA is also present. The anti-BCI antibodies are quite stable, suffering virtually no loss of activity after storage at room temperature for 54 days. Immunoblotting studies indicate that no singular component of the BCI collagen is the prime antigenic component; multiple regions of the collagen molecule are recognized by patients' antibodies.",
author = "McCoy, {J. P.} and Schade, {W. J.} and Siegle, {R. J.} and Waldinger, {T. P.} and Vanderveen, {E. E.} and Neil Swanson",
year = "1985",
doi = "10.1001/archderm.121.8.990",
language = "English (US)",
volume = "121",
pages = "990--994",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Characterization of the humoral immune response to bovine collagen implants

AU - McCoy, J. P.

AU - Schade, W. J.

AU - Siegle, R. J.

AU - Waldinger, T. P.

AU - Vanderveen, E. E.

AU - Swanson, Neil

PY - 1985

Y1 - 1985

N2 - The use of bovine collagen implants (BCIs) for the correction of dermal contour deformities is becoming widespread. A small percentage of patients receiving treatment with BCIs suffer adverse reactions that appear to be of an immune nature. Circulating antibodies to BCIs are found in all patients suffering adverse treatment reactions and in small numbers of normal individuals and BCI-treated patients not suffering adverse reactions. These antibodies are always IgG, although quite often IgA is also present. The anti-BCI antibodies are quite stable, suffering virtually no loss of activity after storage at room temperature for 54 days. Immunoblotting studies indicate that no singular component of the BCI collagen is the prime antigenic component; multiple regions of the collagen molecule are recognized by patients' antibodies.

AB - The use of bovine collagen implants (BCIs) for the correction of dermal contour deformities is becoming widespread. A small percentage of patients receiving treatment with BCIs suffer adverse reactions that appear to be of an immune nature. Circulating antibodies to BCIs are found in all patients suffering adverse treatment reactions and in small numbers of normal individuals and BCI-treated patients not suffering adverse reactions. These antibodies are always IgG, although quite often IgA is also present. The anti-BCI antibodies are quite stable, suffering virtually no loss of activity after storage at room temperature for 54 days. Immunoblotting studies indicate that no singular component of the BCI collagen is the prime antigenic component; multiple regions of the collagen molecule are recognized by patients' antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0021809722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021809722&partnerID=8YFLogxK

U2 - 10.1001/archderm.121.8.990

DO - 10.1001/archderm.121.8.990

M3 - Article

VL - 121

SP - 990

EP - 994

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 8

ER -